In vitro activity of novel rifamycins against Gram-positive clinical isolates

Journal of Antibiotics

Volumn 60, Issue 9, 2007, Pages 572-576

  Murphy, Christopher K ^a   Karginova, Elena ^b   Sahm, Dan ^b   Rothstein, David M ^a  

^a ActivBiotics Inc   (United States)

^b Eurofins Medinet Inc   (Germany)

Author keywords

ABI 0043; MIC; Rifalazil; Rifampin; Staphylococci; Streptococci

Indexed keywords

ABI 0043; ABI 0045; ABI 0090; ABI 0094; ABI 0204; ABI 0273; ABI 0299; ABI 0322; ABI 0338; ABI 0370; ABI 0376; ABI 0418; ABI 0420; ANTIBIOTIC AGENT; BACTERIAL RNA; BENZOXAZINE DERIVATIVE; BENZOXAZINORIFAMYCIN; OXACILLIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFALAZIL; RIFAMPICIN; RIFAMYCIN; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; CYTOCHROME P450;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; COMPARATIVE STUDY; DRUG EFFECT; DRUG INTERACTION; GRAM POSITIVE COCCI; MICROBIOLOGICAL EXAMINATION; STAPHYLOCOCCUS AUREUS;

POSIBACTERIA; STAPHYLOCOCCUS;

ANTI-BACTERIAL AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM-POSITIVE COCCI; MICROBIAL SENSITIVITY TESTS; RIFAMYCINS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

EID: 38449098454     PISSN: 00218820     EISSN: None     Source Type: Journal    
DOI: 10.1038/ja.2007.72     Document Type: Article

References (21)

1. Rothstein DM, Hartman AD, Cynamon MH, Eisenstein BI. Development potential of rifalazil. Expert Opin Investig Drugs 12: 255-271 (2003)
2. Kissling M, Bergamini N. Rifampicin in free combination with other antimicrobial drugs in non-Tb infections. Clinical data on 650 patients (a review). Chemotherapy 27: 368-402 (1981)
3. Smith SM, Eng RH, Tecson-Tumang F. Ciprofloxacin therapy for methicillin-resistant Staphylococcus aureus infections or colonizations. Antimicrob Agents Chemother 33: 181-184 (1989)
4. Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 279: 1537-1541 (1998)
5. Murphy CK, Mullin S, Osburne MS, van Duzer J, J. Siedlecki J, Yu X, Kerstein K, Cynamon M, Rothstein DM. In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 50: 827-834 (2006)
6. Fujii K, Tsuji A, Miyazaki S, Yamaguchi Y, Goto S. In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives. Antimicrob Agents Chemother 38: 1118-1122 (1994)
7. Aubry-Damon H, Soussy C-J, Courvalin P. Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 42: 2590-2594 (1998)
8. Williams DL, Spring L, Collins L, Miller LP, Heifets LB, Gangadharam PR, Gillis TP. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 42: 1853-1857 (1998)
9. Yang BH, Koga H, Ohno H, Ogawa K, Fukuda M, Hirakata Y, Maesaki S, Tomono K, Tashiro T, Kohno S. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. J Antimicrob Chemother 42: 621-628 (1998)
10. Mandell GL, Moorman DR. Treatment of experimental staphylococcal infections: effect of rifampin alone and in combination on development of rifampin resistance. Antimicrob Agents Chemother 17: 658-662 (1980)
11. Wichelhaus TA, Schäfer V, Brade V, Böddinghaus B. Molecular characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 43: 2813-2816 (1999)
12. Wichelhaus TA, Schafer V, Brade V, Boddinghaus B. Differential effect of rpoB mutations on antibacterial activities of rifampicin and KRM-1648 against Staphylococcus aureus. J Antimicrob Chemother 47: 153-156 (2001)
13. Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A, Darst SA. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 104: 901-912 (2001)
14. Kutlin A, Kohlhoff S, Roblin P, Hammerschlag MR, Riska P. Emergence of resistance to rifampin and rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis. Antimicrob Agents Chemother 49: 903-907 (2005)
15. Suchland RJ, Bourillon A, Denamur E, Stamm WE, Rothstein DM. Rifampin-resistant RNA polymerase mutants of Chlamydia trachomatis remain susceptible to the ansamycin rifalazil. Antimicrob Agents Chemother 49: 1120-1126 (2005)
16. Stamm WE, Batteiger BE, McCormack WM, Totten PA, Sternlicht A, Kivel NM, for the Rifalazil Study Group. A Randomized, Double-Blind Study Comparing Single-Dose Rifalazil With Single-Dose Azithromycin for the Empirical Treatment of Nongonococcal Urethritis in Men. Sex Transm Dis. Feb 8; [Epub ahead of print] (2007)
17. Mullin S, Rothstein DM, Murphy CK. Activity of novel benzoxazinorifamycins against rifamycin-resistant Streptococcus pyogenes. Antimicrob Agents Chemother 50: 1908-1909 (2006)
18. Rothstein DM, Farquhar RS, Sirokman K, Sondergaard K, Hazlett C, Doye AA, Gwathmey JK, Mullin S, van Duzer J, Murphy CK. Efficacy of novel rifamycin derivatives against rifamycin-sensitive and -resistant Staphylococcus aureus in murine models of infection. Antimicrob Agents Chemother 50: 3658-3664 (2006)
19. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 16th informational supplement. M100-S16, Clinical and Laboratory Standards Institute, Wayne, Pa. (2006)
20. Rothstein DM, Shalish C, Murphy CK, Sternlicht A, Campbell LA. Development potential of rifalazil and other benzoxazinorifamycins. Expert Opin Investig Drugs 15: 603-623 (2006)
21. Trampuz A, Zimmerli W, Murphy CK, Rothstein DM, Landmann R, Widmer AF. Efficacy of a novel rifamycin ABI-0043 against Staphylococcus aureus in an experimental model of foreign-body infection. Antimicrob Agents Chemother. May 14; [Epub ahead of print] (2007)